The short answer
Vaginal estrogen is a low-dose estrogen cream, tablet, insert, or ring used inside the vagina to treat dryness, burning, painful sex, and urinary symptoms caused by menopause (genitourinary syndrome of menopause, or GSM). Very little reaches the bloodstream. The Menopause Society considers it first-line prescription therapy for GSM, and a progestogen is generally not needed with low-dose products.
Safety essentials
Vaginal estrogen labels do not all say the same thing. As of our October 3, 2026 DailyMed check, Estring's revised label has no boxed warning, while Vagifem, Imvexxy, Estrace vaginal cream, and Premarin vaginal cream still carry the older boxed warning covering endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer, even though blood levels with low-dose vaginal products are far lower than with systemic estrogen. In November 2025 the FDA asked makers of menopausal hormone therapy to remove boxed-warning language about cardiovascular disease, breast cancer, and probable dementia, while keeping the endometrial cancer warning for systemic estrogen-alone products. That is a class-level request: each product's warning changes only when its own label is revised. On February 12, 2026 the FDA approved the first six revised labels (Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva).
Any vaginal bleeding after menopause needs evaluation. People with a history of breast cancer, especially those taking aromatase inhibitors, should decide with their oncology team.
Current label check
The medication-specific claims on this page were checked against these current product labels on 2026-10-03.
| Product label | Label date | Boxed warning on that label |
|---|---|---|
| Vagifem (estradiol) vaginal insert | 2025-02-10 | Endometrial cancer, cardiovascular disorders, probable dementia, breast cancer |
| Imvexxy (estradiol) vaginal insert | 2026-09-29 | Endometrial cancer, cardiovascular disorders, probable dementia, breast cancer |
| Estrace (estradiol) vaginal cream 0.01% | 2024-05-29 | Endometrial cancer, cardiovascular disorders, breast cancer, probable dementia |
| Premarin vaginal cream | 2025-05-30 | Endometrial cancer, cardiovascular disorders, breast cancer, probable dementia |
| Estring (estradiol vaginal system) | 2026-04-23 | None (revised label) |
Established evidence
What vaginal estrogen treats
Lower estrogen thins and dries vaginal and urethral tissue, raises vaginal pH, and changes the microbiome. Symptoms include dryness, irritation, painful sex, urgency, burning with urination, and recurrent urinary tract infections. Unlike hot flashes, GSM usually worsens over time without treatment.
Vaginal estrogen products compared
Vagifem, Yuvafem, and Imvexxy previously had separate pages here; their product details are consolidated in this table.
| Product | Ingredient and form | Typical schedule after start-up | Notes |
|---|---|---|---|
| Vagifem, Yuvafem, generics | Estradiol 10 mcg vaginal insert | Twice weekly | Labeled for atrophic vaginitis due to menopause; Yuvafem is a generic version |
| Imvexxy | Estradiol 4 or 10 mcg softgel insert | Twice weekly | Approved for moderate-to-severe dyspareunia; inserted without an applicator |
| Estrace vaginal cream | Estradiol cream | As prescribed, often 1 to 3 times weekly | Can also be applied to the vulva |
| Premarin vaginal cream | Conjugated estrogens cream | As prescribed | See the Premarin guide |
| Estring | Estradiol ring, about 7.5 mcg per day | Replaced every 90 days | Local dose; different from Femring, which is a systemic ring |
Established evidence
What the evidence shows
Randomized trials show vaginal estrogen improves vaginal cell maturation, pH, dryness, and painful sex, and reduces recurrent urinary tract infections in postmenopausal people. Observational studies have not found increased risks of endometrial cancer, breast cancer, or cardiovascular disease with low-dose vaginal estrogen.
Vaginal estrogen vs systemic estrogen
| Feature | Low-dose vaginal estrogen | Systemic estradiol |
|---|---|---|
| Treats hot flashes | No | Yes |
| Treats GSM | Yes, first-line | Often, but some people still need local therapy |
| Blood estrogen levels | Remain in or near the postmenopausal range | Raised |
| Progestogen needed with a uterus | Generally no | Yes |
Established evidence
Common side effects
- Vaginal discharge or irritation
- Spotting, which should be reported
- Breast tenderness (uncommon at low doses)
Alternatives
Nonhormonal moisturizers and lubricants help mild symptoms. Ospemifene is an oral prescription for painful sex and dryness, and prasterone is a vaginal DHEA insert. Pelvic floor physical therapy helps when muscle tension contributes to pain.
Questions to ask a healthcare professional
- Which form fits my routine and dexterity?
- Is vaginal estrogen safe with my cancer history?
- Do I need it long term?
Questions, answered
What people ask about Vagifem, Yuvafem, Imvexxy, Estring, Estrace cream
Does vaginal estrogen get into the bloodstream?+
A small amount does, but at labeled low doses blood levels generally stay in or near the postmenopausal range.
Is Yuvafem the same as Vagifem?+
Yuvafem is a generic version of Vagifem: the same 10 mcg estradiol vaginal insert.
Do I need progesterone with vaginal estrogen?+
Generally not with low-dose products, according to The Menopause Society. Any bleeding should still be evaluated.
Does vaginal estrogen help bladder symptoms?+
Evidence supports benefit for urgency and recurrent urinary tract infections linked to menopause.
Does Kindr Health offer vaginal estrogen?+
This page is educational. Whether any treatment is appropriate is decided by a licensed professional.
Kindr Health does not claim to offer Vagifem, Yuvafem, Imvexxy, Estring, Estrace cream on this page. Availability and prescribing are not implied.
A broader care pathway
Explore menopause care
Learn how Kindr Health care pathways work. An educational page is not a statement that this medication is available or appropriate for you.
SOURCES & REFERENCES
Every clinical claim on this page is sourced.
- Vagifem prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Vagifem
- Imvexxy prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Imvexxy
- Estring prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Estring
- Estrace vaginal cream prescribing information (current label) (2026) — DailyMed, U.S. National Library of Medicine. dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Estrace%20vaginal%20cream
- The 2020 genitourinary syndrome of menopause position statement (2020) — The Menopause Society (Menopause journal). pubmed.ncbi.nlm.nih.gov/32852449
- FDA initiates removal of boxed warnings from menopausal hormone therapy products (2025) — U.S. Department of Health and Human Services / FDA. www.hhs.gov/press-room/fact-sheet-fda-initiates-removal-of-black-box-warnings-from-menopausal-hormone-replacement-therapy-products.html
- FDA approves labeling changes to menopausal hormone therapy products (first six labels) (2026) — U.S. Food and Drug Administration. www.fda.gov/news-events/press-announcements/fda-approves-labeling-changes-menopausal-hormone-therapy-products
This resource is educational and does not replace individualized medical advice. Do not start, stop, or change a prescription without guidance from a licensed healthcare professional.